







an Open Access Journal by MDPI

DNA Damage in Cancer

Guest Editor:

Prof. Dr. Dik C. van Gent

1: Department of Molecular Genetics, Erasmus MC, PO box 2040, 3000 CA Rotterdam, The Netherlands

2: Oncode Institute, Erasmus MC, PO box 2040, 3000 CA Rotterdam, The Netherlands

Deadline for manuscript submissions:

closed (31 August 2022)

Message from the Guest Editor

Dear Colleagues,

Defects in DNA repair and the DNA damage response are a common phenomenon in cancer development. The causal nature of DNA damage repair defects in carcinogenesis was recognized several decades ago. More recently, this has sparked a new research area that aims to target these defects for personalized anticancer therapies. The first example is PARP inhibitors for hereditary ovarian and breast cancer, but several more approaches are currently being explored. This Special Issue welcomes papers that describe development of such therapies, as well as the various stages to implementation of these approaches in the clinic.

Prof. Dik C. van Gent Guest Editor













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us